JPWO2022239820A1 - - Google Patents
Info
- Publication number
- JPWO2022239820A1 JPWO2022239820A1 JP2023521233A JP2023521233A JPWO2022239820A1 JP WO2022239820 A1 JPWO2022239820 A1 JP WO2022239820A1 JP 2023521233 A JP2023521233 A JP 2023521233A JP 2023521233 A JP2023521233 A JP 2023521233A JP WO2022239820 A1 JPWO2022239820 A1 JP WO2022239820A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021081913 | 2021-05-13 | ||
JP2021086534 | 2021-05-21 | ||
PCT/JP2022/020011 WO2022239820A1 (ja) | 2021-05-13 | 2022-05-12 | 炎症性疾患を治療又は予防するための抗ヒトpd-1アゴニスト抗体及びこれを含有する医薬組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
JPWO2022239820A1 true JPWO2022239820A1 (ja) | 2022-11-17 |
Family
ID=84029692
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023521233A Pending JPWO2022239820A1 (ja) | 2021-05-13 | 2022-05-12 |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP4339289A1 (ja) |
JP (1) | JPWO2022239820A1 (ja) |
KR (1) | KR20240007203A (ja) |
AR (1) | AR125887A1 (ja) |
AU (1) | AU2022272835A1 (ja) |
BR (1) | BR112023023400A2 (ja) |
CA (1) | CA3217199A1 (ja) |
IL (1) | IL307887A (ja) |
MX (1) | MX2023013207A (ja) |
TW (1) | TW202311290A (ja) |
UY (1) | UY39768A (ja) |
WO (1) | WO2022239820A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117024595B (zh) * | 2023-10-08 | 2024-01-26 | 江西乐成欣生生物技术研究有限责任公司 | 抗人st2的单克隆抗体及其应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
US8927697B2 (en) * | 2008-09-12 | 2015-01-06 | Isis Innovation Limited | PD-1 specific antibodies and uses thereof |
TW201134488A (en) * | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
EP3939613A1 (en) * | 2011-08-11 | 2022-01-19 | ONO Pharmaceutical Co., Ltd. | Therapeutic agent for autoimmune diseases comprising pd-1 agonist |
EA201890790A1 (ru) | 2015-09-29 | 2018-10-31 | Селджин Корпорейшн | Связывающие pd-1 белки и способы их применения |
CA3065516A1 (en) * | 2017-06-05 | 2018-12-13 | Janssen Biotech, Inc. | Antibodies that specifically bind pd-1 and methods of use |
TWI804572B (zh) | 2018-02-09 | 2023-06-11 | 日商小野藥品工業股份有限公司 | 雙特異性抗體 |
AR114127A1 (es) | 2018-03-02 | 2020-07-22 | Lilly Co Eli | Anticuerpos agonistas contra pd-1 y usos de estos |
US20210363216A1 (en) | 2018-05-14 | 2021-11-25 | Immunocore Limited | Bifunctional binding polypeptides |
EP3980460A2 (en) | 2019-06-05 | 2022-04-13 | AnaptysBio, Inc. | Pd-1 agonist and method of using same |
JP7185614B2 (ja) | 2019-11-18 | 2022-12-07 | 株式会社エクスモーション | 情報処理装置、及び情報処理プログラム |
JP7310572B2 (ja) | 2019-11-29 | 2023-07-19 | 日本電気株式会社 | 計数装置、制御方法、及びプログラム |
JPWO2021241523A1 (ja) * | 2020-05-25 | 2021-12-02 |
-
2022
- 2022-05-12 JP JP2023521233A patent/JPWO2022239820A1/ja active Pending
- 2022-05-12 WO PCT/JP2022/020011 patent/WO2022239820A1/ja active Application Filing
- 2022-05-12 EP EP22807519.8A patent/EP4339289A1/en active Pending
- 2022-05-12 AU AU2022272835A patent/AU2022272835A1/en active Pending
- 2022-05-12 MX MX2023013207A patent/MX2023013207A/es unknown
- 2022-05-12 BR BR112023023400A patent/BR112023023400A2/pt unknown
- 2022-05-12 IL IL307887A patent/IL307887A/en unknown
- 2022-05-12 CA CA3217199A patent/CA3217199A1/en active Pending
- 2022-05-12 KR KR1020237042168A patent/KR20240007203A/ko unknown
- 2022-05-13 TW TW111118052A patent/TW202311290A/zh unknown
- 2022-05-13 UY UY0001039768A patent/UY39768A/es unknown
- 2022-05-13 AR ARP220101298A patent/AR125887A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
IL307887A (en) | 2023-12-01 |
EP4339289A1 (en) | 2024-03-20 |
UY39768A (es) | 2022-11-30 |
CA3217199A1 (en) | 2022-11-17 |
AU2022272835A1 (en) | 2023-11-02 |
MX2023013207A (es) | 2023-11-15 |
BR112023023400A2 (pt) | 2024-01-23 |
KR20240007203A (ko) | 2024-01-16 |
WO2022239820A1 (ja) | 2022-11-17 |
AU2022272835A9 (en) | 2023-11-16 |
TW202311290A (zh) | 2023-03-16 |
AR125887A1 (es) | 2023-08-23 |
Similar Documents
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20230911 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230911 |